"Organoplatinum Compounds" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Organic compounds which contain platinum as an integral part of the molecule.
Descriptor ID |
D009944
|
MeSH Number(s) |
D02.691.800
|
Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Organoplatinum Compounds".
Below are MeSH descriptors whose meaning is more specific than "Organoplatinum Compounds".
This graph shows the total number of publications written about "Organoplatinum Compounds" by people in this website by year, and whether "Organoplatinum Compounds" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
Year | Major Topic | Minor Topic | Total |
---|
2002 | 0 | 1 | 1 |
2006 | 1 | 0 | 1 |
2007 | 2 | 1 | 3 |
2008 | 1 | 1 | 2 |
2010 | 0 | 2 | 2 |
2011 | 0 | 1 | 1 |
2014 | 0 | 1 | 1 |
2016 | 0 | 1 | 1 |
2021 | 0 | 1 | 1 |
2022 | 0 | 1 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Organoplatinum Compounds" by people in Profiles.
-
Effects of early myocardial reperfusion and perfusion on myocardial necrosis/dysfunction and inflammation in patients with ST-segment and non-ST-segment elevation acute coronary syndrome: results from the PLATelet inhibition and patients Outcomes (PLATO) trial. Eur Heart J Acute Cardiovasc Care. 2022 Jun 07; 11(4):336-349.
-
FOLFOX Therapy Induces Feedback Upregulation of CD44v6 through YB-1 to Maintain Stemness in Colon Initiating Cells. Int J Mol Sci. 2021 Jan 13; 22(2).
-
Preoperative Modified FOLFIRINOX Treatment Followed by Capecitabine-Based Chemoradiation for Borderline Resectable Pancreatic Cancer: Alliance for Clinical Trials in Oncology Trial A021101. JAMA Surg. 2016 08 17; 151(8):e161137.
-
Phase 2 trial of induction gemcitabine, oxaliplatin, and cetuximab followed by selective capecitabine-based chemoradiation in patients with borderline resectable or unresectable locally advanced pancreatic cancer. Int J Radiat Oncol Biol Phys. 2014 Mar 15; 88(4):837-44.
-
Phase I study of two schedules of oral S-1 in combination with fixed doses of oxaliplatin and bevacizumab in patients with advanced solid tumors. Oncology. 2011; 81(2):65-72.
-
Neoadjuvant bevacizumab, oxaliplatin, 5-fluorouracil, and radiation for rectal cancer. Int J Radiat Oncol Biol Phys. 2012 Jan 01; 82(1):124-9.
-
Severe electrolyte disturbances after hyperthermic intraperitoneal chemotherapy: oxaliplatin versus mitomycin C. Ann Surg Oncol. 2011 Jan; 18(1):174-80.
-
Effect of chemotherapeutic stress on induction of vascular endothelial growth factor family members and receptors in human colorectal cancer cells. Mol Cancer Ther. 2008 Sep; 7(9):3064-70.
-
A four-arm, randomized, multicenter phase II trial of oxaliplatin combined with varying schedules of 5-fluorouracil as first-line therapy in previously untreated advanced colorectal cancer. Clin Colorectal Cancer. 2008 Mar; 7(2):134-9.
-
Targeting of insulin-like growth factor-I receptor with a monoclonal antibody inhibits growth of hepatic metastases from human colon carcinoma in mice. Ann Surg Oncol. 2007 Oct; 14(10):2838-46.